我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的隐私政策。
相关临床试验
0
0 进行中
药物批准
4
批准总数
监管机构
1
监管机构数
成立时间
N/A
暂无试验阶段数据
暂无试验数据
FDA
Food and Drug Administration
- Nostrum Laboratories Inc. has voluntarily recalled all lots of Sucralfate Tablets USP 1 gram manufactured after June 2023 following the company's Chapter 11 bankruptcy filing and operational shutdown. - The recall was initiated because the discontinuation of quality control activities means the company cannot assure the product meets identity, strength, quality, and purity specifications. - All recalled lots should be destroyed immediately as the company is not accepting returns, and consumers experiencing problems should contact their healthcare providers. - The medication, used to treat ulcers, was distributed to wholesalers, retailers, manufacturers, medical facilities, and repackagers nationwide.
